全文获取类型
收费全文 | 14811篇 |
免费 | 937篇 |
国内免费 | 95篇 |
专业分类
耳鼻咽喉 | 124篇 |
儿科学 | 495篇 |
妇产科学 | 347篇 |
基础医学 | 2145篇 |
口腔科学 | 251篇 |
临床医学 | 1310篇 |
内科学 | 3609篇 |
皮肤病学 | 448篇 |
神经病学 | 1559篇 |
特种医学 | 307篇 |
外科学 | 1310篇 |
综合类 | 41篇 |
一般理论 | 7篇 |
预防医学 | 1258篇 |
眼科学 | 278篇 |
药学 | 1130篇 |
中国医学 | 40篇 |
肿瘤学 | 1184篇 |
出版年
2024年 | 23篇 |
2023年 | 202篇 |
2022年 | 512篇 |
2021年 | 859篇 |
2020年 | 406篇 |
2019年 | 613篇 |
2018年 | 672篇 |
2017年 | 412篇 |
2016年 | 478篇 |
2015年 | 561篇 |
2014年 | 704篇 |
2013年 | 924篇 |
2012年 | 1290篇 |
2011年 | 1279篇 |
2010年 | 764篇 |
2009年 | 590篇 |
2008年 | 914篇 |
2007年 | 894篇 |
2006年 | 791篇 |
2005年 | 718篇 |
2004年 | 585篇 |
2003年 | 514篇 |
2002年 | 474篇 |
2001年 | 63篇 |
2000年 | 38篇 |
1999年 | 68篇 |
1998年 | 85篇 |
1997年 | 77篇 |
1996年 | 42篇 |
1995年 | 31篇 |
1994年 | 32篇 |
1993年 | 22篇 |
1992年 | 21篇 |
1991年 | 15篇 |
1990年 | 16篇 |
1989年 | 5篇 |
1988年 | 8篇 |
1987年 | 7篇 |
1986年 | 11篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 13篇 |
1982年 | 8篇 |
1981年 | 6篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1977年 | 9篇 |
1975年 | 4篇 |
1974年 | 10篇 |
1973年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Roberto Rivera-Luna Marta Zapata-Tarrés Aurora Medina-Sansón Enrique López-Aguilar Ana Niembro-Zúñiga J. Amador Zarco Alfonso Marhx-Bracho Fernando Rueda-Franco Leticia Bornstein-Quevedo 《Child's nervous system》2007,23(5):543-547
Objective The purpose of this study is to analyze clinical aspects and disease-free survival (DFS) in children less than 3 years of
age diagnosed with low-grade astrocytoma.
Methods In a period of 24 years (1980–2004), a total of 43 (5.4%) children were registered with these characteristics. Twenty-three
patients had pilocytic astrocytoma, 18 diffused, and 2 mixed. Thirty-one (72.1%) children had incomplete surgical tumor resection
and 12 (27.9%) had a complete tumor resection. Twelve (27.9%) patients had cranial radiotherapy and 17 (39.5%) received chemotherapy.
Overall survival was recorded in 23 (53%). DFS was 50% at 250 months of follow-up for the whole group. DFS for the supratentorial
group was 60% at 250 months, whereas, for the infratentorial, it was 22% at 120 months (p = 0.008).
Conclusion The only favorable prognostic pattern was the supratentorial presentation. Radiotherapy and chemotherapy did not alter the
outcome. 相似文献
13.
Clemens Aigner Peter Jaksch Samy Mazhar Kriztina Czebe Gabriel Marta Sharokh Taghavi Georg Lang Walter Klepetko 《European journal of cardio-thoracic surgery》2004,25(2):184-187
OBJECTIVES: The use of OKT3 for treatment of advanced high-grade acute rejection episodes eventually can result in cytokine release and consecutive pulmonary edema. Temporary extracorporeal membrane oxygenation (ECMO) bridging can be used to overcome this crucial period before the beneficial effects of OKT3 can be observed. METHODS: We summarize our experience with three patients, who underwent lung transplantation and presented with severe acute rejection episodes. OKT3 had to be initiated due to insufficient response to standard rejection therapy with corticosteroids. Upon initiation of OKT3 treatment, a massive life-threatening deterioration of lung function in spite of heavily invasive respirator treatment was seen and temporary ECMO support was imperative to support graft function. Results of this treatment were retrospectively reviewed. RESULTS: In all cases femoro-femoral veno-arterial ECMO was used for support of the impaired graft and after a period of 4-5 days led to a massive improvement of graft function. In the further course two patients could be discharged from hospital and are still alive 30 and 36 months, respectively, after the described incident. One patient died 4 months later due to liver failure. CONCLUSIONS: We conclude that the use of ECMO support in patients experiencing significant side effects from OKT3 therapy is a useful and effective therapeutic tool to overcome the initial critical period until the lung has sufficiently recovered. 相似文献
14.
15.
Avasimibe is a novel orally bioavailable ACAT inhibitor, currently under clinical development (phase III trials). It was safe when administered to rats, dogs, and humans. In vitro studies in human macrophages demonstrated that avasimibe reduces foam cell formation not only by enhancing free cholesterol efflux, but also by inhibiting the uptake of modified LDL. The concentration‐dependent reduction in cellular cholesteryl ester content in these cells was not accompanied by an increase in intracellular free cholesterol, which is in agreement with a good safety profile for avasimibe. In the liver, avasimibe caused a significant reduction in the secretion of apo B and apo B‐containing lipoproteins into plasma. Avasimibe induced cholesterol 7α‐hydroxylase and increased bile acid synthesis in cultured rat hepatocytes, and its administration to rats did not produce an increase in lithogenicity index of the bile. The hypolipidemic efficacy of the compound was demonstrated in cholesterol‐fed as well as in non‐cholesterol‐fed animals. In these models, plasma cholesterol levels were reduced, mainly due to the decrease in the non‐HDL cholesterol fraction. Clinical data are scarce, but in a study performed in 130 men and women with combined hyperlipidemia and hypoalphalipoproteinemia, avasimibe, 50–500 mg/day, significantly reduced plasma total triglyceride and VLDL‐cholesterol. Although total cholesterol, LDL‐cholesterol, and HDL‐cholesterol were unchanged, it must be stressed that animal data suggest that avasimibe may have direct antiatherosclerotic activity in addition to its cholesterol‐lowering effect. Avasimibe treatment can also contribute to increase plaque stability, as it reduces the accumulation of lipids in the arterial wall, inhibits macrophage infiltration into the media and reduces matrix metalloproteinase expression and activity. Moreover, avasimibe and statins have been shown to have synergistic effects, and the combination therapy may not only inhibit atherosclerotic lesion progression but also induce lesion regression, independently of changes in plasma cholesterol. 相似文献
16.
Antonio Amoroso Pierluigi Garzia Marta Vadacca Sara Galluzzo Flavia Del Porto Anna P Mitterhofer Antonella Afeltra 《The Journal of adolescent health》2003,32(1):94-97
We report on a 26-year-old female affected by Noonan syndrome (NS), a congenital disorder characterized by various phenotypic features and congenital anomalies) associated with a variety of autoimmune diseases, including systemic lupus erythematosus, celiac disease, and Hashimoto thyroiditis. Autoimmunity is seldom described in NS and the association between this congenital disease and three autoimmune disorders has not been previously reported. Should the occurrence of autoimmune disorders in NS be confirmed, a relevant clinical and laboratory evaluation of NS patients should be performed in order to clarify whether the immune system involvement represents only an occasional event or is a feature of the disease. 相似文献
17.
18.
19.
20.
Carlos Calderón Rafael Rotaeche Arritxu Etxebarria Mercé Marzo Rosa Rico Marta Barandiaran 《BMC health services research》2006,6(1):138-11